Navigation Links
Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
Date:6/4/2011

gating the potential predictive benefit of CTCs in metastatic prostate cancer clinical trials as there are limited ways of assessing therapeutic benefit in this disease, especially when it has metastasized to the bone."

Additional studies are underway to further validate CTCs as a surrogate endpoint in metastatic prostate cancer studies.

Study Design

The CTC analysis was conducted to determine if CTCs could be used as a surrogate for overall survival.  It was performed in 900 of the 1195 enrolled study patients with metastatic castration-resistant prostate cancer post-docetaxel being treated with either abiraterone acetate plus prednisone or placebo plus prednisone.  CTCs were counted (cells/7.5 mL) along with other biomarkers including PSA, LDH, hemoglobin, alkaline phosphatase at screening and baseline and post-baseline at four, eight and 12 weeks. Analyses were conducted for these biomarkers individually and collectively.

Veridex provided product support for the study. 

Dr. Howard Scher has provided consulting services to the company. 

Additional Data Presented at ASCO Substantiates In Vitro Diagnostic Use of CELLSEARCH® CTC Test

An independent study investigating the in vitro diagnostic use of CTC testing found that the number of CTCs in the blood may help physicians more reliably assess treatment benefit for patients with metastatic breast cancer.  The study, a large-scale retrospective analysis using blinded data to create a pooled dataset of 841 patients from cancer centers around the world, found that CTC count at or above the threshold of five was reliably associated with disease progression.  Further, the predictive value of CTCs was not affected by treatment type (chemotherapy, endocrine therapy, biologic therapy), tumor type (hormone receptor positive/negative, HER2 positive/negative),
'/>"/>

SOURCE Veridex, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
2. American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA
3. American Stroke Association Late-Breaking Science Report: Antiplatelet Drug May Be Better Than Aspirin in Preventing Recurrent Strokes
4. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Oral Drug Reduces Cardiac Events in Primary PCI Patients
5. American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis
6. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
7. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
8. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
11. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... announced agreement to purchase the Interventional business of ... Boston Scientific to offer physicians and healthcare systems ... challenging vascular conditions. The addition of ... technologies supports the Boston Scientific strategy to provide ...
(Date:9/2/2014)... DIEGO , Sept. 2, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... be participating in the Morgan Stanley Healthcare conference ... by Scott Huennekens , president and chief ...
(Date:9/2/2014)... , Sept. 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has granted orphan drug ... hypertension. "The FDA Office of Orphan ... from sponsors to identify and designate drug candidates that ... evaluation and development of such products," said Craig ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... SUNNYVALE, Calif., July 7, 2011 Cepheid (Nasdaq: ... for its 2011 second quarter ended June 30, 2011, on ... The company will host a management presentation at ... discuss the results.  To access the live webcast, please visit ...
... just three weeks after hearing oral argument, the First District ... judgment against Johnson & Johnson (NYSE: JNJ ) ... death case involving their Duragesic® fentanyl pain patch. ... in DiCosolo v. ALZA Corp, et al ., obtained ...
Cached Medicine Technology:Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 3
(Date:9/2/2014)... September 02, 2014 The Dream2Walk Foundation along ... on Sept. 14th, 2014 during Spinal Cord Injury Awareness Month ... Lynn England, and Chuck Ligon. Linear Automotive will be there ... show. , Doors open at 2pm. The car show is ... one free pass to the concert. There will be trophies ...
(Date:9/2/2014)... Kathleen Doheny HealthDay ... The U.S. obesity epidemic is a driving force behind the ... study. Researchers looked at data from five national surveys ... increase in diabetes over time could be explained by factors ... U.S. adults. The investigators found that the prevalence of ...
(Date:9/2/2014)... By Steven Reinberg ... (HealthDay News) -- Stimulant medications -- such as Adderall, ... (ADHD) in children, won,t stunt their growth, a new ... final height as adults," said study researcher Dr. Slavica ... Clinic in Rochester, Minn. Katusic noted that results ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. 2, 2014 ... loss by blocking a certain nerve linked to appetite and ... patients. Using electric impulses to block the vagus nerve, ... suppress feelings of hunger. And, they did, just not to ... the nerve that connects the brain to the gut can ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Drinking and marijuana may ... a new study suggests. Researchers analyzed 2007 to ... school seniors who said they had used alcohol or ... drinking alcohol was associated with more unsafe driving, damage ... about actions while under the influence of alcohol, especially ...
Breaking Medicine News(10 mins):Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 2Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2
... be making us hungrier, so we eat more, which in ... Yang and his colleagues at the Lawson Health Research Institute ... tissue can reproduce a hormone that stimulates fat cell production. ... way we think about and treat abdominal obesity. , Yang ...
... 16 Skanska USA Building Inc.,announced today that ... service the,growing Indiana construction markets. The announcement was ... Midwest operations., "Indiana is a strong construction ... "Skanska is an industry leader and after,working in ...
... Facing the ... Healthcare Industry, ... with U.S. News & World Report,hosted an exclusive panel discussion ... National Press Club in Washington, D.C.,The event, attended by Congressional ...
... with a faulty breast cancer gene could be at ... genes, according to research published this month in the ... University of Pennsylvania School of Medicine join an international ... 10,000 women carrying a BRCA1 or BRCA2 mutation for ...
... the source should lead to more effective vaccines, researchers say ... strains of virus that produce seasonal flu epidemics start in ... of the world, researchers report. , And by focusing on ... to improve their forecast of seasonal flu strains and develop ...
... Ala. - New clinical data showed some cancer patients ... AME-133v, said a researcher at the University of Alabama ... 15th during the 2008 annual meeting of the American ... 1 clinical trial data showed AME-133v had a potent ...
Cached Medicine News:Health News:Your belly fat could be making you hungrier 2Health News:Skanska Opens Indianapolis Office 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 3Health News:Breast cancer risk amplified by additional genes in combo with BRCA mutation 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: